What Is PT-141/Bremelanotide and How Does It Work
Bremelanotide is a synthetic cyclic peptide developed by Palatin Technologies from Melanotan-2, modified to act more selectively at the melanocortin MC3R and MC4R receptors in the central nervous system. Rather than working peripherally on blood flow the way PDE5 inhibitors like sildenafil do, bremelanotide activates arousal-related pathways centrally, in the hypothalamus - a mechanistically distinct approach to sexual dysfunction. An earlier intranasal formulation was in development but was halted after the FDA raised concerns in 2007 about blood-pressure elevations seen in testing; the compound was later reformulated as a subcutaneous injection and pursued for a narrower, defined indication.
Two products, two regulatory categories: Vyleesi (bremelanotide) is an FDA-approved prescription autoinjector, approved in 2019 specifically for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, manufactured under FDA quality controls and backed by published Phase 3 randomized controlled trial data. "PT-141" sold by research-chemical and peptide suppliers - including for off-label use in men - is a separate, unapproved product. Even though it is chemically the same molecule, it has not been evaluated by the FDA for safety, purity, or efficacy in that unregulated form, and it is not the same legal or safety category as Vyleesi. This article treats those as two distinct things throughout, not interchangeable products.
Dosing: Approved Vyleesi vs. Unapproved "PT-141"
The approved product has a defined, FDA-reviewed dosing regimen. The unapproved research-chemical version does not - doses cited in online "PT-141 protocols" come from supplier and community convention, not an FDA-reviewed dose-finding program, and the actual potency of an unregulated vial is not independently verified.
| Product | Dose | Frequency | Route |
|---|---|---|---|
| Vyleesi (FDA-approved) | 1.75mg | As needed, ~45 min before activity; max 1 dose/24h, max 8/month | SubQ autoinjector |
| "PT-141" research chemical (unapproved) | No approved or validated dose | Varies by supplier/community protocol | Self-reconstituted SubQ injection |
Context: Some prescribers use bremelanotide off-label in men, drawing on the approved Vyleesi product and their own clinical judgment - that is a legal use of an approved drug. That is a different situation from an individual buying unlabeled "PT-141" powder from a research-chemical website and self-dosing without a prescription, verified purity, or medical supervision.
Regulatory Status
Vyleesi (bremelanotide) received FDA approval in 2019 for acquired, generalized HSDD in premenopausal women, following two Phase 3 randomized controlled trials. It carries a boxed warning for transient increases in blood pressure and is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. Physicians retain the ability to prescribe an approved drug off-label for other patients based on clinical judgment - a normal and legal part of medical practice.
Separately, "PT-141" sold by research-chemical and peptide suppliers has not been evaluated or approved by the FDA in that form. It is typically marketed as being for laboratory research use only, not for human consumption. Quality is a documented concern: FDA warning-letter testing of research-chemical bremelanotide products has found actual potency ranging from as low as 62% to as high as 141% of the labeled amount, meaning a buyer cannot reliably know how much active peptide is actually in a given vial. These two products - the approved autoinjector and the unapproved research-chemical vial - should not be treated as equivalent in safety, quality, or legal status, even though the underlying molecule is the same.
What Research Shows
Bremelanotide's approval rests on two identical Phase 3, randomized, double-blind, placebo-controlled trials (the RECONNECT studies) in premenopausal women with HSDD, which found statistically significant improvements in sexual desire and related distress compared with placebo. Nausea was the most commonly reported side effect, affecting roughly 40% of patients, along with flushing and headache; a minority of patients discontinued due to nausea. This is a comparatively strong human clinical evidence base for the approved indication. Evidence for bremelanotide's off-label use in men - for erectile dysfunction or low libido - is considerably thinner, drawn mostly from smaller or earlier-phase studies rather than the large controlled trials behind the Vyleesi approval, and it has not been evaluated by the FDA for use in men.
Bremelanotide was derived from Melanotan-2 - see the Melanotan-2 reference for how the parent compound's broader, non-selective receptor activity differs from bremelanotide's more targeted mechanism.